Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies

By The Science Advisory Board staff writers

September 17, 2020 -- Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.

Currently, Lilly is evaluating several potential neutralizing antibodies, such as LY-CoV-555, for the prevention and/or treatment of COVID-19 as monotherapies or in combination. Through the collaboration, the companies will have the ability to quickly scale up production of antibody therapies that are successful in clinical testing and receive regulatory approval.

The companies hope to be able to produce millions of doses in 2021.

Eli Lilly rolls out early COVID-19 antibody trial data
Eli Lilly released early data from a phase II clinical trial that explored the use of the neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...
Lilly begins phase III trial of COVID-19 antibody treatment
Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter